Bioelectrical impedance analysis (BIA) is a non-invasive, portable method for estimating body composition by measuring how tissues resist and react to a low-level electrical current. In malnutrition and sarcopenia assessment, it is used because frameworks such as GLIM and EWGSOP2 require objective evaluation of reduced muscle mass or muscle quantity, while many clinical settings need a bedside alternative to DXA.

Informational only — not medical advice; clinicians should consult current society guidelines.

GLIM criteria & muscle mass

The Global Leadership Initiative on Malnutrition (GLIM) framework is an international consensus approach to diagnosing malnutrition in clinical settings. Under GLIM, diagnosis requires at least one phenotypic criterion and at least one etiologic criterion. BIA can support the phenotypic criterion of reduced muscle mass by estimating measures such as fat-free mass index (FFMI) or appendicular skeletal muscle index (ASMI).

The research brief identifies FFMI thresholds of <17.0 kg/m² for men and <15.0 kg/m² for women, and ASMI thresholds of <7.0 kg/m² for men and <5.5 kg/m² for women. These values should be interpreted within the full GLIM diagnostic process, because low BIA-derived muscle mass alone does not establish malnutrition without an etiologic criterion such as reduced food intake or disease-related inflammation.

EWGSOP2 sarcopenia & BIA

The 2019 European Working Group on Sarcopenia in Older People update places low muscle strength at the start of sarcopenia case-finding, then uses muscle quantity to confirm the diagnosis. BIA fits the Confirm stage of the Find-Assess-Confirm-Severity pathway by measuring muscle quantity when a practical body-composition method is needed.

The research brief lists low muscle quantity thresholds of appendicular skeletal muscle mass <20.0 kg for men and <15.0 kg for women, and ASMI <7.0 kg/m² for men and <5.5 kg/m² for women. EWGSOP2 grades sarcopenia as severe when low muscle quantity is accompanied by low muscle strength and low physical performance, such as low grip strength and slow gait speed.

ESPEN guidance

ESPEN guidance describes BIA as a clinical body-composition method for nutritional assessment and monitoring. Beyond fat-free mass and body fat, the brief highlights body cell mass as the metabolically active body component relevant to nutritional depletion in catabolic states.

BIA can also estimate total body water, although reliability declines in severe fluid or electrolyte imbalance. ESPEN also identifies phase angle as a useful impedance-derived marker because it is not dependent on weight-based predictive equations in the same way as some body-composition estimates.

Phase angle as a prognostic marker

Phase angle reflects the relationship between resistance and reactance and is commonly interpreted as a marker of cell membrane integrity and body cell mass. Higher phase angle is associated with healthier cell membranes and larger cell mass, while lower phase angle may suggest cellular deterioration, malnutrition, or higher clinical risk.

The research brief lists phase-angle values <5.0° for men and <4.6° for women as malnutrition-risk thresholds, and values ≤4.05° for men and ≤3.55° for women as linked to sarcopenia in community-dwelling older adults. It also notes standardized phase angle thresholds such as <-1.65 or -2.0 standard deviations from age- and sex-adjusted norms in research. Across oncology, renal failure, and ICU settings, low phase angle values below roughly 4.5°-5.0° are described as independent predictors of shorter survival in the brief.

BIA vs DXA validity/limitations

DXA remains the higher-precision reference method for body composition because it estimates fat mass, lean mass, and bone mineral content. BIA is the practical alternative for bedside screening and longitudinal monitoring, but its estimates are more sensitive to hydration status and prediction equations.

Dimension	DXA	BIA
Body model	Three-compartment model: fat mass, lean mass, bone.	Two-compartment model: fat mass and fat-free mass.
Accuracy pattern	High precision for reference body-composition assessment.	High population correlation in the brief, but higher individual variability.
Hydration limits	Assumes relatively constant lean-tissue hydration.	Dehydration can overestimate fat; edema can overestimate muscle.
BMI extremes	Generally accurate, though severe obesity can affect attenuation.	May underestimate fat in obesity and overestimate fat in very lean patients.

For procurement and workflow context, see the related BIA vs DXA procurement guide and the bioimpedance supplier due-diligence questions. For supplier and validation workflows, see clinical device sourcing.

Clinical settings

Oncology: BIA is used for detection of cancer cachexia and monitoring muscle loss. The research brief identifies low phase angle as an independent prognostic marker in oncology settings.

Renal and dialysis care: BIA is used for dry weight estimation through extracellular-water and total-body-water measures, and for monitoring protein-energy wasting. The brief notes KDOQI guidance to measure BIA at least 30 minutes post-dialysis for stability.

Geriatrics and aged care: BIA can support assessment of frailty, low appendicular skeletal muscle mass, and sarcopenic obesity, particularly where DXA access is impractical.

ICU: In critical care, BIA use focuses on fluid status and rapid muscle wasting. The research brief notes that low admission phase angle correlates with increased mortality and longer stays.

Key clinical references

• GLIM Criteria for Malnutrition (2019): Journal of Parenteral and Enteral Nutrition
• EWGSOP2 Sarcopenia Consensus (2019): Age and Ageing
• ESPEN Guidelines on BIA in clinical practice: Clinical Nutrition
• KDOQI Nutrition in CKD (2020 Update): American Journal of Kidney Diseases
• Phase Angle as Prognostic Marker: Nutrients
• BIA in the ICU (ESPEN 2023): Clinical Nutrition
• Sarcopenic Obesity Guidelines (ESPEN/EASO): Obesity Facts

Bioelectrical impedance analysis (BIA) is a non-invasive, portable method for estimating body composition by measuring how tissues resist and react to a low-level electrical current. In malnutrition and sarcopenia assessment, it is used because frameworks such as GLIM and EWGSOP2 require objective evaluation of reduced muscle mass or muscle quantity, while many clinical settings need a bedside alternative to DXA.

Informational only — not medical advice; clinicians should consult current society guidelines.

For the full clinical reference, switch to EN.

Bioelectrical impedance analysis (BIA) is a non-invasive, portable method for estimating body composition by measuring how tissues resist and react to a low-level electrical current. In malnutrition and sarcopenia assessment, it is used because frameworks such as GLIM and EWGSOP2 require objective evaluation of reduced muscle mass or muscle quantity, while many clinical settings need a bedside alternative to DXA.

Informational only — not medical advice; clinicians should consult current society guidelines.

For the full clinical reference, switch to EN.